Corium International Inc. (NASDAQ:CORI) has been given a $9.00 price target by investment analysts at Jefferies Group in a report released on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s target price points to a potential upside of 63.34% from the stock’s previous close.

CORI has been the topic of a number of other reports. Needham & Company LLC reissued a “buy” rating and set a $15.00 price target on shares of Corium International in a report on Monday, September 26th. Zacks Investment Research downgraded shares of Corium International from a “hold” rating to a “sell” rating in a report on Tuesday, October 11th. Leerink Swann set a $16.00 price objective on shares of Corium International and gave the company a “buy” rating in a report on Tuesday, November 22nd. Finally, FBR & Co reaffirmed a “buy” rating and set a $18.00 price objective on shares of Corium International in a report on Tuesday, November 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $12.25.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Corium International (NASDAQ:CORI) opened at 5.51 on Thursday. Corium International has a one year low of $3.14 and a one year high of $9.93. The company’s 50-day moving average is $5.02 and its 200 day moving average is $4.72. The company’s market capitalization is $122.36 million.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of United States and international copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/28/corium-international-inc-cori-given-a-9-00-price-target-by-jefferies-group-analysts.html.

Institutional investors have recently bought and sold shares of the company. Opaleye Management Inc. increased its position in Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,000 shares in the last quarter. RTW Investments LLC increased its position in Corium International by 3.0% in the second quarter. RTW Investments LLC now owns 852,961 shares of the biopharmaceutical company’s stock valued at $2,960,000 after buying an additional 24,629 shares in the last quarter. Finally, Paloma Partners Management Co acquired a new position in Corium International during the second quarter valued at $152,000. 88.35% of the stock is currently owned by hedge funds and other institutional investors.

Corium International Company Profile

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

5 Day Chart for NASDAQ:CORI

Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.